Copyright
©The Author(s) 2018.
World J Gastroenterol. Oct 28, 2018; 24(40): 4606-4614
Published online Oct 28, 2018. doi: 10.3748/wjg.v24.i40.4606
Published online Oct 28, 2018. doi: 10.3748/wjg.v24.i40.4606
Table 1 Patients’ basic characteristics n (%)
| Total (n = 48365) | Compensated HBV group1 (n = 45683) | Decompensated cirrhosis group(n = 2682) | aP value | |
| Sex (male) | 32691 (67.6) | 30881 (67.6) | 1810 (67.5) | 0.9214 |
| Age (yr) | 43.5 ± 12.3 | 43.0 ± 12.2 | 51.7 ± 11.5 | < 0.0001 |
| Nucleos(t)ide analog | ||||
| Entecavir | 20147 (41.7) | 18644 (40.8) | 1503 (56.0) | < 0.0001 |
| Lamivudine | 8411 (17.4) | 7937 (17.4) | 474 (17.7) | 0.7105 |
| Clevudine | 3029 (6.3) | 2898 (6.3) | 131 (4.9) | 0.0028 |
| Lamivudine + adefovir | 2525 (5.2) | 2415 (5.3) | 110 (4.1) | 0.0084 |
| Telbivudine | 32 (0.1) | 30 (0.1) | 2 (0.1) | 1.0000 |
| Others | 14221 (29.4) | 13759 (30.1) | 462 (17.2) | < 0.0001 |
| Medication compliance | ||||
| < 25% | 12793 (26.5) | 12045 (26.4) | 748 (27.9) | 0.0700 |
| 25%-50% | 6067 (12.5) | 5769 (12.6) | 298 (11.1) | 0.0229 |
| 50%-75% | 7075 (14.6) | 6686 (14.6) | 389 (14.5) | 0.8735 |
| > 75% | 22430 (46.4) | 21183 (46.4) | 1247 (46.5) | 0.9835 |
| Type of first decompensation | ||||
| Refractory ascites | 2022 (55.6) | 2022 (55.6) | ||
| Varix bleeding | 711 (19.6) | 711 (19.6) | ||
| Hepatorenal syndrome | 151 (4.2) | 151 (4.2) | ||
| Hepatic encephalopathy | 752 (20.7) | 752 (20.7) |
Table 2 Rate of clinical progression of liver disease
| Compensated chronic hepatitis B (n = 45683) | Decompensated cirrhosis (n = 2682) | |||||||||||||||||
| Newly decompensated incidence(n = 3401) | Hepatoma incidence(n = 5268) | Mortality incidence(n = 1415) | Second decompensated incidence(n = 1626) | Hepatoma incidence(n = 1295) | Mortality incidence(n = 874) | |||||||||||||
| Event | Percent | Accumulation (%) | Event | Percent | Accumulation (%) | Event | Percent | Accumulation (%) | Event | Percent | Accumulation (%) | Event | Percent | Accumulation (%) | Event | Percent | Accumulation (%) | |
| < 1 yr | 923 | 2.02% | 2.02% | 1602 | 3.51% | 3.51% | 253 | 0.55% | 0.55% | 1257 | 46.87% | 46.87% | 765 | 14.26% | 14.26% | 513 | 19.13% | 19.13% |
| 1-2 yr | 662 | 1.45% | 3.47% | 1053 | 2.31% | 5.81% | 249 | 0.55% | 1.10% | 144 | 5.37% | 52.24% | 200 | 3.73% | 17.99% | 132 | 4.92% | 24.05% |
| 2-3 yr | 634 | 1.39% | 4.86% | 947 | 2.07% | 7.88% | 280 | 0.61% | 1.71% | 99 | 3.69% | 55.93% | 140 | 2.61% | 20.60% | 94 | 3.50% | 27.55% |
| 3-4 yr | 631 | 1.38% | 6.24% | 802 | 1.76% | 9.64% | 324 | 0.71% | 2.42% | 71 | 2.65% | 58.58% | 94 | 1.75% | 22.35% | 65 | 2.42% | 29.98% |
| 4-5 yr | 551 | 1.21% | 7.44% | 864 | 1.89% | 11.53% | 309 | 0.68% | 3.10% | 55 | 2.05% | 60.63% | 96 | 1.79% | 24.14% | 70 | 2.61% | 32.59% |
| aP for trend | < 0.0001 | < 0.0001 | 0.0004 | < 0.0001 | < 0.0001 | < 0.0001 | ||||||||||||
- Citation: Ju YC, Jun DW, Choi J, Saeed WK, Lee HY, Oh HW. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis. World J Gastroenterol 2018; 24(40): 4606-4614
- URL: https://www.wjgnet.com/1007-9327/full/v24/i40/4606.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i40.4606